Compound Identified as Potential Colorectal Cancer Inhibitor
Researchers have discovered that Lespedezaflavanone H acts as an inhibitor against the protein PRMT4 in cancer cells.
Updated on Oct. 22, 2026 in Cancer
Scientists have identified the compound Lespedezaflavanone H as a potential inhibitor of PRMT4, a protein often associated with cancer progression. The compound demonstrated significant activity in suppressing the growth of various colorectal cancer cell lines.
Why it matters
Identifying new inhibitors for proteins like PRMT4 is critical for developing targeted therapies that can selectively disrupt cancer cell proliferation. This discovery provides a foundation for future research into using Lespedezaflavanone H as a potential anticancer agent.
The compound Lespedezaflavanone H shows an IC50 of 1.73 µM against PRMT4, with anti-proliferation effects on colorectal lines ranging from 2.32 µM in SW620 cells to 11.26 µM in LS180 cells.
The details
Molecular docking studies confirmed that the compound forms hydrogen bonds with specific residues, ASN-265 and ARG-267, within the PRMT4 protein. Further molecular dynamics simulations verified that this binding interaction between the protein and Lespedezaflavanone H remains stable.
Health Landscape
This study advances PRMT4-targeted cancer therapy research by identifying a novel molecule capable of inhibiting the protein's activity. The findings contribute to the growing body of work focused on developing small-molecule inhibitors to disrupt oncogenic signaling pathways.
While this discovery is currently limited to laboratory analysis, it paves the way for potential future clinical trials targeting colorectal cancer. Patients should note that this compound is not currently available for medical use or as a treatment option.
The takeaway
The study underscores the potential for natural compounds to serve as precise inhibitors in cancer treatment protocols. Continued investigation will be necessary to determine if these laboratory results can translate into viable therapeutic applications for humans.
Further reading
For more information on the latest breakthroughs in oncology, visit the Cancer research section.
Source note: This article includes information reported by Nature.
